Liver Cirrhosis
Conditions
Interventions
Case Group:none
Sponsors
900th Hospital of PLA Joint Logistic Support Force
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for the Case Group: (1) Patients aged between 18 and 75 years; (2) Meeting the diagnostic criteria for cirrhosis with portal hypertension; (3) Patients presenting with esophagogastric variceal bleeding or recurrent, refractory ascites, who have failed conservative medical treatment and are scheduled to undergo elective TIPS procedure; (4) Patients who voluntarily sign an informed consent form after being fully informed of the study’s purpose and significance. Inclusion Criteria for the Control Group: (1) Age and sex matched with the case group; (2) Patients who voluntarily sign an informed consent form after being fully informed of the study’s purpose and significance.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for the Case Group: (1) Patients with portal hypertension manifestations such as EGVB, refractory ascites, or pleural effusion caused by non-cirrhotic portal hypertension; (2) Patients with ongoing active gastrointestinal bleeding; (3) Patients with active systemic or intestinal infections, including peritonitis or intra-abdominal infections; (4) Patients with concurrent malignant tumors; (5) Patients who have used antibiotics, prebiotics, probiotics, or proton pump inhibitors within the past 4 weeks; (6) Patients with gastrointestinal diseases such as ulcerative colitis, Crohn’s disease, diarrhea, or constipation; (7) Patients with contraindications to the TIPS procedure; (8) Patients who are unwilling to sign the informed consent form. Exclusion Criteria for the Control Group: Individuals diagnosed with cirrhotic portal hypertension, hypertension, diabetes, inflammatory bowel disease, acute gastroenteritis, or other acute or chronic conditions; Individuals who have used antibiotics, probiotics, prebiotics, or other medications that may affect intestinal function or gut microbiota within the past 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alpha-Diversity;liver function;Gut Microbiota Composition; | — |
Secondary
| Measure | Time frame |
|---|---|
| liver function;renal function; | — |
Countries
China
Contacts
Public ContactDongliang Li
900th Hospital of PLA Joint Logistic Support Force
Outcome results
None listed